Gavin Giovannoni Selected Research

Relapsing-Remitting Multiple Sclerosis

6/2022	Cladribine Tablets for Relapsing-Remitting Multiple Sclerosis: A Clinician's Review.
1/2022	Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.
1/2022	Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data.
1/2022	Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
1/2022	Prevalence of disability improvement in relapsing-remitting multiple sclerosis patients treated with cladribine tablets.
1/2021	Antibodies to neurofilament light as potential biomarkers in multiple sclerosis.
12/2020	Overview of Differences and Similarities of Published Mixed Treatment Comparisons on Pharmaceutical Interventions for Multiple Sclerosis.
10/2020	Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study.
6/2020	Socioeconomic status and disease-modifying therapy prescribing patterns in people with multiple sclerosis.
1/2019	Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gavin Giovannoni Research Topics

Disease

184	Multiple Sclerosis 11/2022 - 10/2002
56	Relapsing-Remitting Multiple Sclerosis 06/2022 - 09/2003
16	Chronic Progressive Multiple Sclerosis 09/2022 - 09/2003
16	Disease Progression 10/2019 - 10/2004
12	Infections 11/2021 - 02/2012
10	Atrophy 01/2022 - 12/2010
10	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2017 - 05/2005
9	COVID-19 08/2022 - 01/2020
9	Demyelinating Diseases (Demyelinating Disease) 06/2022 - 04/2003
8	Inflammation (Inflammations) 06/2022 - 05/2005
8	Lymphopenia (Lymphocytopenia) 07/2021 - 02/2010
6	Neurodegenerative Diseases (Neurodegenerative Disease) 06/2022 - 01/2010
6	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 04/2007
6	Neoplasms (Cancer) 01/2020 - 01/2017
6	Movement Disorders (Movement Disorder) 11/2014 - 08/2004
5	Progressive Multifocal Leukoencephalopathy 01/2022 - 04/2010
5	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 10/2020 - 03/2014
5	Nervous System Diseases (Neurological Disorders) 11/2014 - 11/2006
5	Obsessive-Compulsive Disorder (Disorder, Obsessive-Compulsive) 05/2012 - 08/2004
5	Chorea (Rheumatic Chorea) 04/2009 - 03/2003
4	Infectious Mononucleosis (Glandular Fever) 10/2020 - 01/2009
4	Neuromyelitis Optica (Devic's Disease) 09/2020 - 01/2011
4	Herpes Zoster 04/2019 - 02/2010
4	Parkinson Disease (Parkinson's Disease) 01/2018 - 05/2008
4	Streptococcal Infections (Streptococcal Infection) 05/2012 - 08/2004
3	Epstein-Barr Virus Infections 01/2022 - 06/2007
3	Headache (Headaches) 07/2021 - 11/2014
3	Chickenpox 01/2019 - 01/2009
3	Hypersensitivity (Allergy) 01/2019 - 03/2006
3	Neuroinflammatory Diseases 01/2017 - 01/2011
3	Optic Neuritis (Retrobulbar Neuritis) 03/2016 - 06/2008
3	Encephalitis (Encephalitis, Rasmussen) 08/2010 - 01/2004
2	Rheumatoid Arthritis 08/2021 - 07/2012
2	Nausea 07/2021 - 09/2012
2	Opportunistic Infections (Opportunistic Infection) 04/2019 - 11/2018
2	Human Influenza (Influenza) 01/2019 - 01/2004
2	Meningitis 01/2019 - 08/2010
2	Urinary Tract Infections (Urinary Tract Infection) 01/2019 - 07/2016
2	HIV Infections (HIV Infection) 08/2018 - 01/2015
2	Vitamin D Deficiency 02/2018 - 07/2013
2	Hypertension (High Blood Pressure) 01/2018 - 12/2012
2	Spinal Cord Injuries (Spinal Cord Injury) 01/2018 - 03/2015
2	Body Weight (Weight, Body) 01/2018 - 02/2010
2	Ulcerative Colitis 07/2016 - 07/2012
2	Exanthema (Rash) 03/2016 - 06/2013

Drug/Important Bio-Agent (IBA)

31	Cladribine FDA LinkGeneric 06/2022 - 02/2010
29	AntibodiesIBA 11/2021 - 11/2003
26	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2006
22	TabletsIBA 06/2022 - 02/2010
18	Alemtuzumab (Campath)FDA Link 01/2022 - 03/2012
18	Natalizumab (Tysabri)FDA Link 01/2022 - 03/2006
15	Dimethyl FumarateIBA 01/2018 - 09/2012
14	Fingolimod Hydrochloride (FTY720)FDA Link 08/2022 - 07/2011
13	InterferonsIBA 01/2021 - 09/2004
13	Interferon beta-1a FDA Link 01/2018 - 10/2004
12	Interferon-betaIBA 01/2015 - 09/2003
11	Monoclonal AntibodiesIBA 11/2022 - 03/2012
11	Vitamin D FDA LinkGeneric 01/2020 - 06/2007
10	Pharmaceutical PreparationsIBA 01/2022 - 05/2010
8	ocrelizumabIBA 10/2022 - 01/2017
8	siponimodIBA 09/2022 - 02/2017
8	Proteins (Proteins, Gene)FDA Link 08/2021 - 12/2008
8	Daclizumab (Zenapax)FDA Link 10/2020 - 06/2013
8	CannabinoidsIBA 08/2017 - 05/2003
7	Neutralizing AntibodiesIBA 11/2021 - 06/2007
7	GadoliniumIBA 01/2020 - 07/2006
6	AntigensIBA 11/2021 - 05/2005
5	VaccinesIBA 08/2022 - 06/2020
5	HLA-DRB1 Chains (HLA DRB1)IBA 10/2020 - 01/2010
5	Immunoglobulin G (IgG)IBA 01/2013 - 01/2003
4	Sphingosine-1-Phosphate ReceptorsIBA 09/2022 - 07/2011
4	Neuroprotective AgentsIBA 01/2020 - 01/2013
4	Glatiramer Acetate (Copaxone)FDA Link 02/2017 - 05/2005
4	EnzymesIBA 07/2016 - 03/2006
4	daclizumab HYPIBA 05/2014 - 06/2013
3	Immunoglobulins (Immunoglobulin)IBA 01/2022 - 10/2019
3	Indicators and Reagents (Reagents)IBA 08/2021 - 12/2014
3	Oligoclonal BandsIBA 10/2019 - 04/2003
3	Rituximab (Mabthera)FDA Link 02/2017 - 03/2016
3	AutoantibodiesIBA 05/2015 - 03/2003
3	Biological ProductsIBA 09/2014 - 07/2009
3	Neural Cell Adhesion Molecules (Neural Cell Adhesion Molecule)IBA 06/2013 - 08/2010
2	opicinumabIBA 02/2022 - 01/2019
2	Biotin (Vitamin H)FDA Link 02/2022 - 12/2020
2	Cytidine Diphosphate (CDP)IBA 01/2022 - 12/2018
2	COVID-19 VaccinesIBA 01/2022 - 01/2021
2	AutoantigensIBA 11/2021 - 03/2006
2	RNA (Ribonucleic Acid)IBA 10/2020 - 01/2004
2	Transaminases (Aminotransferases)IBA 01/2018 - 09/2012
2	Dopamine (Intropin)FDA LinkGeneric 01/2018 - 07/2009
2	Minocycline (Cyclops)FDA LinkGeneric 01/2018 - 03/2015
2	Gonadal HormonesIBA 11/2016 - 10/2014
2	CytokinesIBA 04/2016 - 01/2013
2	Sodium Channels (Sodium Channel)IBA 03/2016 - 01/2014
2	Voltage-Gated Sodium ChannelsIBA 03/2016 - 06/2015
2	Salivary Proteins and PeptidesIBA 12/2015 - 10/2015

Therapy/Procedure

60	Therapeutics 10/2022 - 11/2003
7	Immunotherapy 04/2021 - 05/2005
2	Injections 11/2021 - 05/2018
2	Precision Medicine 11/2021 - 11/2017